ClinicalTrials.Veeva

Menu
M

Maple Leaf Research | Toronto, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Emtricitabine
Tenofovir Alafenamide
TDF
Doravirine
Islatravir
Rilpivirine
TAF
FTC
Tenofovir Disoproxil Fumarate
Retatrutide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 23 total trials

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with...

Active, not recruiting
HIV Infection
Drug: DOR/ISL

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabete...

Active, not recruiting
Type 2 Diabetes
Drug: LY3457263
Drug: Placebo

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The...

Enrolling
Obesity
Drug: Retatrutide
Drug: Placebo

The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: DOR/ISL
Drug: ART

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Retatrutide
Drug: Semaglutide

The safety and tolerability of MK-8591A, a 2-drug fixed dose combination (FDC) of doravirine (DOR 100mg) and islatravir (ISL 0.75mg) will be evaluate...

Active, not recruiting
HIV-1 Infection
Drug: MK-8591A

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Active, not recruiting
HIV-1-infection
Drug: Stable Baseline Regimen
Drug: Bictegravir

Trial sponsors

Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo
Lilly logo
U
University of British Columbia logo
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems